Secondary Congenital Glaucoma Medication
- Author: Inci Irak Dersu, MD, MPH; Chief Editor: Hampton Roy, Sr, MD more...
Medications that decrease the aqueous production or increase the outflow are used as initial treatment in adult-onset secondary congenital glaucoma.
These agents decrease aqueous production and IOP.
May reduce elevated and normal IOP, with or without glaucoma, by reducing production of aqueous humor or by outflow.
Nonselective beta-adrenergic blocking agent that lowers intraocular pressure by reducing aqueous humor production and possibly increases outflow of aqueous humor.
These agents decrease IOP.
Lowers IOP by decreasing aqueous production and increasing uveoscleral outflow.
Prostaglandin F2-alpha analogs
These agents decrease IOP by increasing uveoscleral outflow.
May decrease IOP by increasing outflow of aqueous humor.
A prostamide analogue with ocular hypotensive activity. Mimics the IOP-lowering activity of prostamides via the prostamide pathway. Used to reduce IOP in open-angle glaucoma or ocular hypertension.
Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension.
Prostaglandin F2-alpha analog and selective FP prostanoid receptor agonist. Exact mechanism of action unknown but believed to reduce IOP by increasing uveoscleral outflow.
These agents decrease IOP by increasing aqueous humor outflow.
Increase outflow by pulling the longitudinal part of the ciliary muscle. Indirect-acting miotics are used less commonly.
Carbonic anhydrase inhibitors
Decrease aqueous production and IOP. May use temporarily before surgery or longer, if patient tolerates it. Concomitant use of topical and systemic carbonic anhydrase inhibitors is not recommended.
Inhibits enzyme carbonic anhydrase, reducing rate of aqueous humor formation, which, in turn, reduces IOP. Acetazolamide increases sickling in patients with sickle cell trait or disease; in these patients, methazolamide may be safer.
Reduces aqueous humor formation by inhibiting enzyme carbonic anhydrase, which results in decreased IOP.
Inhibits carbonic anhydrase, which, in turn, leads to a decrease in aqueous humor secretion. May use concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, administer drugs at least 10 min apart.
Dorzolamide (Trusopt) 2%)
Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one ophthalmic drug is being used, administer the drugs at least 10 min apart. Inhibits carbonic anhydrase, which, in turn, leads to a decrease in aqueous humor secretion.
Lopes JE, Wilson RR, Alvim HS, Shields CL, Shields JA, Calhoun J, et al. Central corneal thickness in pediatric glaucoma. J Pediatr Ophthalmol Strabismus. 2007 Mar-Apr. 44(2):112-7. [Medline].
Iwach AG, Hoskins HD Jr, Hetherington J Jr, Shaffer RN. Analysis of surgical and medical management of glaucoma in Sturge-Weber syndrome. Ophthalmology. 1990 Jul. 97(7):904-9. [Medline].
Agarwal HC, Sandramouli S, Sihota R, Sood NN. Sturge-Weber syndrome: management of glaucoma with combined trabeculotomy-trabeculectomy. Ophthalmic Surg. 1993 Jun. 24(6):399-402. [Medline].
Kargi SH, Koc F, Biglan AW, Davis JS. Visual acuity in children with glaucoma. Ophthalmology. 2006 Feb. 113(2):229-38. [Medline].
Yang LL, Lambert SR, Lynn MJ, Stulting RD. Surgical management of glaucoma in infants and children with Peters' anomaly: long-term structural and functional outcome. Ophthalmology. 2004 Jan. 111(1):112-7. [Medline].
Allingham R, Damji K, Freedman S, Moroi S, Shafranov G. Developmental glaucomas with associated anomalies. Shields' Textbook of Glaucoma. 5th ed. Philadelphia, PA 19106: Lippincott Williams & Wilkins; 2005. 252-271.
Cantor LB. Glaucoma associated with congenital disorders. Ritch R, ed. The Glaucomas. St Louis: Mosby; 1989. Vol 2: 931-960.
Eibschitz-Tsimhoni M, Lichter PR, Del Monte MA, Archer SM, Musch DC, Schertzer RM, et al. Assessing the need for posterior sclerotomy at the time of filtering surgery in patients with Sturge-Weber syndrome. Ophthalmology. 2003 Jul. 110(7):1361-3. [Medline].
Facts and Comparisons. Drug Facts and Comparisons. St Louis; 1999.
Freedman S, Walton D. Glaucoma in infants and children. Nelson L, Olitsky S, eds. Harley's Pediatric Ophthalmology. 5th ed. Philadelphia, PA 19106: Lippincott Williams & Wilkins; 2005. Chapter 14, 285-304.
Hittner HM. Aniridia. Ritch R, ed. The Glaucomas. St Louis: Mosby; 1989. Vol 2: 869-884.
Kirwan JF, Shah P, Khaw PT. Diode laser cyclophotocoagulation: role in the management of refractory pediatric glaucomas. Ophthalmology. 2002 Feb. 109(2):316-23. [Medline].
Schottenstein EM. Peter's anomaly. Ritch R, ed. The Glaucomas. St Louis: Mosby; 1989. Vol 2.: 897-903.
Shields MB. Axenfeld-Rieger syndrome. Ritch R, ed. The Glaucomas. St Louis, Mo: Mosby; 1989. Vol 2: 885-95.
Singh OS. Nanophthalmos guidelines for diagnosis and therapy. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2000. Vol 4: 2846-2859.
Walsh J, Muldoon T. Glaucoma associated with retinal vitreoretinal disorders. Ritch R, Shield MB, Krupin T, eds. The Glaucomas. 1996. Vol 2: 1055-1071.
Weiss JS, Ritch R. Glaucoma in the phakomatoses. Ritch R, ed. The Glaucomas. St Louis: Mosby; 1989. Vol 2: 905-29.
Wilson ME, Buckley EG, Kivlin JD. Pediatric Ophthalmology and Strabismus. AAO, Basic and Clinical Science Course. 1998. 6:330-345.